Tom Dineen - Concepedia

Author

Tom Dineen

Blueprint Medicines (United States)

Also Known As

T. Dineen, Tom Dineen

Publications

157

Citations

H-Index

Concepts

All Affiliations

Blueprint Medicines (United States)Yonsei University

About

Tom Dineen is an author at Blueprint Medicines (United States) specializing in medicine, pharmacology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	147
2	Cell Biology	3	3	51
3	Natural Sciences	1	1	34
4	Biochemistry	1	1	34
5	Molecular Medicine	1	1	24

Tom Dineen

Publications

147

Citations

H-Index

Page 1

	Year	Citations
1296P BLU-945, a highly potent and selective 4th generation EGFR TKI for the treatment of EGFR T790M/C797S resistant NSCLC Stefanie S. Schalm, Tom Dineen, Sangbin Lim, Annals of Oncology Drug TargetingMedicineSelective 4ThGeneration Egfr TkiPharmacotherapy	2020	50
Screening for lysine-specific demethylase-1 inhibitors using a label-free high-throughput mass spectrometry assay Matthew Plant, Tom Dineen, Alan C. Cheng, Analytical Biochemistry Medicinal ChemistryDrug TargetBiochemistryMedicineNatural Sciences	2011	34
Abstract 1262: BLU-701 is a highly potent, brain-penetrant and WT-sparing next-generation EGFR TKI for the treatment of sensitizing (ex19del, L858R) and C797S resistance mutations in metastatic NSCLC Chiara Conti, John Campbell, Rich Woessner, Cancer Research Metastatic NsclcPathologyKinase InhibitorsC797s Resistance MutationsTumor Biology	2021	24
Abstract 1467: BLU-945, a fourth-generation, potent and highly selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) with intracranial activity, demonstrates robust <i>in vivo</i> antitumor activity in models of osimertinib-resistant non-small cell lung cancer (NSCLC) Sun Min Lim, Chae Won Park, Zhuo Zhang, Cancer Research Lung AdenocarcinomaPathologyAbstract 1467Resistance MutationsCancer Biology	2021	17
384P BLU-945, a highly potent and selective 4th generation EGFR TKI for the treatment of EGFR T790M/C797S resistant NSCLC Stefanie S. Schalm, Tom Dineen, Sangbin Lim, Annals of Oncology Drug TargetingMedicineSelective 4ThGeneration Egfr TkiPharmacotherapy	2020	12
Abstract 3328: Antitumor activity of BLU-945 and BLU-701 as single agents and in combination in <i>EGFR</i> L858R-driven models of NSCLC Luz Tavera, Stefanie S. Schalm, John Campbell, Cancer Research Antitumor ActivityPathologyCancer DeathCancer BiologyCancer Cell Biology	2022	10

Page 1